The therapeutic area diseases of the musculoskeletal system is currently comprised of xx medicinal products with xx procedures regarding conditions such as arthritis, systemic lupus erythematosus (SLE) or rheumatoid arthritis. In its resolutions, the G-BA has divided the patients into xx subpopulations. If these are weighted according to their patient share in the resolution, xx% of the subpopulations have seen a major additional benefit, XX% have seen a considerable additional benefit and a further XX% of the subpopulations have seen a minor additional benefit in relation to the comparative therapy. While XX% of the subpopulations have been able to record a non-quantifiable additional benefit in relation to the comparative therapy, XX% of the subpopulations have shown no additional benefit. This corresponds to xx% of all xx million patients suitable for treatment with the assessed medicinal products.